AbCellera Biologics Inc. Phase 2 ABCL635 Top-Line Results Conference Call Transcript
Good afternoon, and welcome to the ABCL635 Phase 2 clinical update. My name is Jonathan, and I will facilitate the audio portion of today's interactive broadcast. (Operator Instructions)
At this time, I would like to turn the call over to Tryn Stimart, Chief Legal and Compliance Officer. You may proceed.
Good morning, good afternoon, and good evening, everyone. I am Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. We are pleased to welcome you to AbCellera's conference call to discuss our Phase 2 top-line data for ABCL635. Speaking on the call today are Carl Hansen, AbCellera's President and Chief Executive Officer; Sarah Noonberg, AbCellera's Chief Medical Officer; and Dr. Kelsey Mills, an obstetrician and gynecologist specializing in complex menopause care.
During this call, we may make forward-looking statements based on our current expectations and in accordance with the safe harbor provisions of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
